To Be Discontinued Granule Pulmonary/Allergy
Montelukast Sodium Granule · 2 active FDA presentation rows for this drug
Brand: SINGULAIR
FDA lists Montelukast Sodium Granule as To Be Discontinued (Organon).
No availability text on this FDA row.
Montelukast Sodium Granule: To Be Discontinued
FDA availability text is not recorded on this row. 2 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Montelukast Sodium Granule
- Manufacturer
- Organon
- Dosage Form
- Granule
- Presentation
- Singulair, Granule, 4 mg (NDC 78206-171-01)
- Package NDC
- 78206-171-01
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Mar 24, 2025
- Last Updated
- Mar 24, 2025
- Therapeutic Category
- Pulmonary/Allergy
Row fields from the FDA Drug Shortages database via openFDA.
Full Drug Profile
montelukast
Side effects, interactions, warnings & more